Dennis J Baumgardner1,2,3, Alexander Schwank1,2, Jessica J F Kram1,2,3, Wilhelm Lehmann1,3, Jacob L Bidwell1,3, Tricia La Fratta1, Kenneth Copeland4. 1. Aurora UW Medical Group, Advocate Aurora Health, Milwaukee, WI. 2. Center for Urban Population Health, Milwaukee, WI. 3. Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI. 4. ACL Laboratories, Advocate Aurora Health, Milwaukee, WI.
Abstract
PURPOSE: Medical trainees are likely at differential risk of exposure to COVID-19 per respective clinical activity. We sought to determine the seroprevalence of COVID-19 antibody (Ab) among resident and fellow physicians with varying degrees of exposure to COVID-19. METHODS: A cross-sectional study of Milwaukee-based resident and fellow physicians, encompassing December 2019-June 2020, was conducted. Relevant variables of interest were ascertained by survey and payroll data, and Abbott ARCHITECT Ab test (index cut-off of ≥1.4) was performed. Descriptive statistics were generated, with 95% CI calculated for the study's primary outcome of seroprevalence. RESULTS: Among survey respondents (92 of 148, 62%), 61% were male, 44% were non-White, mean age was 31 years, 94% had no underlying conditions, and 52% were either family or internal medicine residents. During the study period, ≥32% reported cough, headache, or sore throat and 62% traveled outside of Wisconsin. Overall, 83% thought they had a COVID-19 exposure at work and 33% outside of work; 100% expressed any exposure. Of those exposed at work, 56% received COVID-19 pay, variously receiving 69 mean hours (range: 0-452). Ultimately, 82% (75 of 92) had an Ab test completed; 1 individual (1.3%; 95% CI: 0.0-3.9) tested seropositive, was not previously diagnosed, and had received COVID-19 pay. CONCLUSIONS: The low Ab seroprevalence found in resident and fellow physicians was similar to the concurrently reported 3.7% Ab-positive rate among 2456 Milwaukee-based staff in the same integrated health system. Ultimately, COVID-19 seroconversion may be nominal in properly protected resident and fellow physicians despite known potential exposures.
PURPOSE: Medical trainees are likely at differential risk of exposure to COVID-19 per respective clinical activity. We sought to determine the seroprevalence of COVID-19 antibody (Ab) among resident and fellow physicians with varying degrees of exposure to COVID-19. METHODS: A cross-sectional study of Milwaukee-based resident and fellow physicians, encompassing December 2019-June 2020, was conducted. Relevant variables of interest were ascertained by survey and payroll data, and Abbott ARCHITECT Ab test (index cut-off of ≥1.4) was performed. Descriptive statistics were generated, with 95% CI calculated for the study's primary outcome of seroprevalence. RESULTS: Among survey respondents (92 of 148, 62%), 61% were male, 44% were non-White, mean age was 31 years, 94% had no underlying conditions, and 52% were either family or internal medicine residents. During the study period, ≥32% reported cough, headache, or sore throat and 62% traveled outside of Wisconsin. Overall, 83% thought they had a COVID-19 exposure at work and 33% outside of work; 100% expressed any exposure. Of those exposed at work, 56% received COVID-19 pay, variously receiving 69 mean hours (range: 0-452). Ultimately, 82% (75 of 92) had an Ab test completed; 1 individual (1.3%; 95% CI: 0.0-3.9) tested seropositive, was not previously diagnosed, and had received COVID-19 pay. CONCLUSIONS: The low Ab seroprevalence found in resident and fellow physicians was similar to the concurrently reported 3.7% Ab-positive rate among 2456 Milwaukee-based staff in the same integrated health system. Ultimately, COVID-19 seroconversion may be nominal in properly protected resident and fellow physicians despite known potential exposures.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Hannah F Fung; Leonardo Martinez; Fernando Alarid-Escudero; Joshua A Salomon; David M Studdert; Jason R Andrews; Jeremy D Goldhaber-Fiebert Journal: Clin Infect Dis Date: 2021-07-30 Impact factor: 20.999
Authors: Tyler J Ripperger; Jennifer L Uhrlaub; Makiko Watanabe; Rachel Wong; Yvonne Castaneda; Hannah A Pizzato; Mallory R Thompson; Christine Bradshaw; Craig C Weinkauf; Christian Bime; Heidi L Erickson; Kenneth Knox; Billie Bixby; Sairam Parthasarathy; Sachin Chaudhary; Bhupinder Natt; Elaine Cristan; Tammer El Aini; Franz Rischard; Janet Campion; Madhav Chopra; Michael Insel; Afshin Sam; James L Knepler; Andrew P Capaldi; Catherine M Spier; Michael D Dake; Taylor Edwards; Matthew E Kaplan; Serena Jain Scott; Cameron Hypes; Jarrod Mosier; David T Harris; Bonnie J LaFleur; Ryan Sprissler; Janko Nikolich-Žugich; Deepta Bhattacharya Journal: Immunity Date: 2020-10-14 Impact factor: 31.745
Authors: Lara J Akinbami; Nga Vuong; Lyle R Petersen; Samira Sami; Anita Patel; Susan L Lukacs; Lisa Mackey; Lisa A Grohskopf; Amy Shehu; Jenny Atas Journal: Emerg Infect Dis Date: 2020-09-21 Impact factor: 6.883
Authors: William T Hu; J Christina Howell; Tugba Ozturk; Karima Benameur; Leda C Bassit; Richard Ramonell; Kevin S Cashman; Shama Pirmohammed; John D Roback; Vincent C Marconi; Irene Yang; Valerie V Mac; Daniel Smith; Ignacio Sanz; Whitney Wharton; F Eun-Hyung Lee; Raymond F Schinazi Journal: Emerg Infect Dis Date: 2020-08-28 Impact factor: 6.883